Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 2
2016 2
2017 4
2018 8
2019 4
2020 6
2021 3
2022 4
2023 1
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Results by year

Filters applied: . Clear all
Page 1
Cabozantinib sensitizes microsatellite stable colorectal cancer to immune checkpoint blockade by immune modulation in human immune system mouse models.
Lang J, Leal AD, Marín-Jiménez JA, Hartman SJ, Shulman J, Navarro NM, Lewis MS, Capasso A, Bagby SM, Yacob BW, MacBeth M, Freed BM, Eckhardt SG, Jordan K, Blatchford PJ, Pelanda R, Lieu CH, Messersmith WA, Pitts TM. Lang J, et al. Among authors: bagby sm. Front Oncol. 2022 Nov 7;12:877635. doi: 10.3389/fonc.2022.877635. eCollection 2022. Front Oncol. 2022. PMID: 36419897 Free PMC article.
Pancreatic Ductal Adenocarcinoma Cells Regulate NLRP3 Activation to Generate a Tolerogenic Microenvironment.
Amo-Aparicio J, Dominguez A, Atif SM, Dinarello A, Azam T, Alula KM, Piper M, Lieu CH, Lentz RW, Leal AD, Bagby SM, Messersmith WA, Karam SD, Dinarello CA, Pitts TM, Marchetti C. Amo-Aparicio J, et al. Among authors: bagby sm. Cancer Res Commun. 2023 Sep 20;3(9):1899-1911. doi: 10.1158/2767-9764.CRC-23-0065. Cancer Res Commun. 2023. PMID: 37772994 Free PMC article.
Preclinical Development of the Class-I-Selective Histone Deacetylase Inhibitor OKI-179 for the Treatment of Solid Tumors.
Diamond JR, Pitts TM, Ungermannova D, Nasveschuk CG, Zhang G, Phillips AJ, Bagby SM, Pafford J, Yacob BW, Newton TP, Tentler JJ, Gittleman B, Hartman SJ, DeMattei JA, Winkler JD, Wendt MK, Schiemann WP, Eckhardt SG, Liu X, Piscopio AD. Diamond JR, et al. Among authors: bagby sm. Mol Cancer Ther. 2022 Mar 1;21(3):397-406. doi: 10.1158/1535-7163.MCT-21-0455. Mol Cancer Ther. 2022. PMID: 34965958 Free PMC article.
MCL1 inhibitors S63845/MIK665 plus Navitoclax synergistically kill difficult-to-treat melanoma cells.
Mukherjee N, Skees J, Todd KJ, West DA, Lambert KA, Robinson WA, Amato CM, Couts KL, Van Gulick R, MacBeth M, Nassar K, Tan AC, Zhai Z, Fujita M, Bagby SM, Dart CR, Lambert JR, Norris DA, Shellman YG. Mukherjee N, et al. Among authors: bagby sm. Cell Death Dis. 2020 Jun 8;11(6):443. doi: 10.1038/s41419-020-2646-2. Cell Death Dis. 2020. PMID: 32513939 Free PMC article.
Development of new preclinical models to advance adrenocortical carcinoma research.
Kiseljak-Vassiliades K, Zhang Y, Bagby SM, Kar A, Pozdeyev N, Xu M, Gowan K, Sharma V, Raeburn CD, Albuja-Cruz M, Jones KL, Fishbein L, Schweppe RE, Somerset H, Pitts TM, Leong S, Wierman ME. Kiseljak-Vassiliades K, et al. Among authors: bagby sm. Endocr Relat Cancer. 2018 Apr;25(4):437-451. doi: 10.1530/ERC-17-0447. Epub 2018 Jan 25. Endocr Relat Cancer. 2018. PMID: 29371329 Free PMC article.
BRAF fusions identified in melanomas have variable treatment responses and phenotypes.
Turner JA, Bemis JGT, Bagby SM, Capasso A, Yacob BW, Chimed TS, Van Gulick R, Lee H, Tobin R, Tentler JJ, Pitts T, McCarter M, Robinson WA, Couts KL. Turner JA, et al. Among authors: bagby sm. Oncogene. 2019 Feb;38(8):1296-1308. doi: 10.1038/s41388-018-0514-7. Epub 2018 Sep 25. Oncogene. 2019. PMID: 30254212
34 results